BONE DISEASE IN MULTIPLE MYELOMA
Open Access
- 1 December 1998
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 103 (4) , 902-910
- https://doi.org/10.1046/j.1365-2141.1998.01082.x
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trialBritish Journal of Haematology, 1998
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- Soluble interleukin‐6 receptor as a prognostic factor in multiple myelomaBritish Journal of Haematology, 1996
- The Effect of Hepatocyte Growth Factor on the Behavior of OsteoclastsBiochemical and Biophysical Research Communications, 1995
- Lack of IL‐1 secretion from human myeloma cells highly purified by immunomagnetic separationBritish Journal of Haematology, 1993
- Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesisBiochemical and Biophysical Research Communications, 1989
- Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell linesCancer, 1989
- Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma CellsNew England Journal of Medicine, 1987
- Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple MyelomaMetabolic Bone Disease and Related Research, 1982
- Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple MyelomaNew England Journal of Medicine, 1980